iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with HR-positive, HER2-negative Early Breast Cancer By Ogkologos - November 14, 2024 752 0 Facebook Twitter Google+ Pinterest WhatsApp Final invasive disease-free survival results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Fosnetupitant Is Valuable in the Prophylaxis of Acute, Delayed, and Beyond... November 30, 2021 Treatment for Children with Leukemia Also Effective for Adolescents, Young Adults February 25, 2019 EMA Recommends Granting a Marketing Authorisation for Tebentafusp March 31, 2022 Can Some People with Breast Cancer Safely Skip Lymph Node Radiation? January 23, 2024 Load more HOT NEWS FDA Approves Avelumab for Urothelial Carcinoma Maintenance Treatment Cancer in My Community: Bringing Palliative Care to People With Cancer... Managing Cancer Pain: Are Better Approaches on the Horizon? Could proton beam therapy improve throat cancer treatment?
